Viewing data from:

NOVOLOG MIX 50/50

BLA

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT | B021810 | NOVO NORDISK INC

1 product0 Purple Book patents

Biologic LOENo LOE data

No exclusivity dates or listed patents found in Purple Book

Purple Book Patents

No listed patents in Purple Book.

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 21810 | 2 presentations

351(a) ReferenceVoluntarily RevokedCDERInjectable Suspension

Proper Name

insulin aspart protamine and insulin aspart

Applicant

Novo Nordisk Inc.

Approval Date

26-Aug-08

150UNITS/3ML (50UNITS/ML); 150UNITS/3ML (50UNITS/ML) — Multi-Dose Cartridge (Subcutaneous)

150UNITS/3ML (50UNITS/ML); 150UNITS/3ML (50UNITS/ML) — Autoinjector (Subcutaneous)

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

7 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — 50 UNITS/ML;50 UNITS/ML

▴

INJECTABLE;SUBCUTANEOUS | Approved: 2008-08-26 00:00:00

No patent or exclusivity listings for this strength.